Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06128369 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery
A Phase 3 study, sponsored by Oculis.
- Terminated
- Registry status
- Phase 3
- Development phase
- 117
- Enrollment target
NCT06128369 is a Phase 3 study that was terminated before completion, run by Oculis. The registered enrollment target is 117 participants.
The verdict
NCT06128369, a Phase 3 study, was terminated before completion, sponsored by Oculis.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 117 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to evaluate the efficacy and safety of OCS-01 in treating inflammation and pain in subjects following cataract surgery.
Interventions
- DRUG Dexamethasone Ophthalmic Suspension
- OTHER Vehicle of OCS-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2023-12-18 |
| Est. Completion | 2024-05-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06128369
The ClinicalTrials.gov registry entry for NCT06128369 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oculis, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone Ophthalmic Suspension is the first listed.
NCT06128369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06128369 about?
NCT06128369 is a clinical study titled "Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery". The goal of this clinical trial is to evaluate the efficacy and safety of OCS-01 in treating inflammation and pain in subjects following cataract surgery.
What is the current status of trial NCT06128369?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 117 participants. The study started on 2023-12-18. Estimated completion is 2024-05-09.
What interventions are being tested in trial NCT06128369?
The interventions under investigation include: Dexamethasone Ophthalmic Suspension (DRUG), Vehicle of OCS-01 (OTHER).
Who is sponsoring clinical trial NCT06128369?
This trial is sponsored by Oculis, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.